Heiko Götte

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 12

Top Topics

Replacement Therapy

Advanced Non Small Cell Lung Cancer

Top Venues

Pharmaceutical statistics

Biometrical journal. Biometrische Zeitschrift

Journal of biopharmaceutical statistics

Statistics in medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Stig Johan Wiklund, Katharine Thorn, Heiko Götte, Kimberley Hacquoil, Gaelle Saint-Hilary, Alex Carlton, null null
Going beyond probability of success: Opportunities for statisticians to influence quantitative decision-making at the portfolio level. Pharmaceutical statistics (2024)
Stig Johan Wiklund, Katharine Thorn, Heiko Götte, Kimberley Hacquoil, Gaelle Saint-Hilary, Alex Carlton, null null
Going beyond probability of success: Opportunities for statisticians to influence quantitative decision-making at the portfolio level. Pharmaceutical statistics 23 (3) (2024)
Heiko Götte, Marietta Kirchner, Johannes Krisam, Arthur Allignol, Armin Schueler, Meinhard Kieser
Estimation of treatment effects in early-phase randomized clinical trials involving external control data. Journal of biopharmaceutical statistics (2023)
Heiko Götte, Marietta Kirchner, Johannes Krisam, Arthur Allignol, Francois-Xavier Lamy, Armin Schueler, Meinhard Kieser
An adaptive design for early clinical development including interim decision for single-arm trial with external controls or randomized trial. Pharmaceutical statistics 21 (3) (2022)
Pranab Ghosh, Robin Ristl, Franz Koenig, Martin Posch, Christopher Jennison, Heiko Götte, Armin Schueler, Cyrus R Mehta
Robust group sequential designs for trials with survival endpoints and delayed response. Biometrical journal. Biometrische Zeitschrift 64 (2) (2021)
Robert Miltenberger, Heiko Götte, Armin Schüler, Antje Jahn-Eimermacher
Progression-free survival in oncological clinical studies: Assessment time bias and methods for its correction. Pharmaceutical statistics 20 (4) (2021)
Heiko Götte, Junyuan Xiong, Marietta Kirchner, Hakan Demirtas, Meinhard Kieser
Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival. Pharmaceutical statistics 19 (6) (2020)
Robin Ristl, Nicolás M Ballarini, Heiko Götte, Armin Schueler, Martin Posch, Franz Koenig
Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology. Pharmaceutical statistics 20 (1) (2020)
Heiko Götte, Marietta Kirchner, Meinhard Kieser
Adjustment for exploratory cut-off selection in randomized clinical trials with survival endpoint. Biometrical journal. Biometrische Zeitschrift 62 (3) (2019)
Meinhard Kieser, Marietta Kirchner, Eva Dölger, Heiko Götte
Optimal planning of phase II/III programs for clinical trials with multiple endpoints. Pharmaceutical statistics 17 (5) (2018)
Heiko Götte, Marietta Kirchner, Martin Oliver Sailer
Probability of success for phase III after exploratory biomarker analysis in phase II. Pharmaceutical statistics 16 (3) (2017)
Heiko Götte, Marietta Kirchner, Martin Oliver Sailer, Meinhard Kieser
Simulation-based adjustment after exploratory biomarker subgroup selection in phase II. Statistics in medicine 36 (15) (2017)